A5004924183- Coronary Interventions and Diagnostics
- Acute Myocardial Infarction Research
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac Imaging and Diagnostics
- Cardiac Valve Diseases and Treatments
- Atrial Fibrillation Management and Outcomes
- Venous Thromboembolism Diagnosis and Management
- Cerebrovascular and Carotid Artery Diseases
- Cardiac Arrest and Resuscitation
- Peripheral Artery Disease Management
- Heart Failure Treatment and Management
- Aortic aneurysm repair treatments
- Mechanical Circulatory Support Devices
- Cancer-related molecular mechanisms research
- Epigenetics and DNA Methylation
- Sepsis Diagnosis and Treatment
- Cardiac, Anesthesia and Surgical Outcomes
- Cardiac Health and Mental Health
- Cardiac Arrhythmias and Treatments
- Cardiovascular Function and Risk Factors
- Protein Kinase Regulation and GTPase Signaling
- Cardiac Structural Anomalies and Repair
- Health Systems, Economic Evaluations, Quality of Life
- Ultrasound in Clinical Applications
- Cardiac electrophysiology and arrhythmias
University Medical Center Utrecht
2019-2024
Maasstad Ziekenhuis
2014-2023
Heidelberg University
2023
University Hospital Heidelberg
2023
Athens Euroclinic
2023
Utrecht University
2020-2022
Amsterdam University Medical Centers
2019-2022
Gaustad Hospital
2017
Ludwig-Maximilians-Universität München
2017
Institut Cardiovasculaire Paris Sud
2017
Ischemic heart disease is a major cause of out-of-hospital cardiac arrest. The role immediate coronary angiography and percutaneous intervention (PCI) in the treatment patients who have been successfully resuscitated after arrest absence ST-segment elevation myocardial infarction (STEMI) remains uncertain.
This study sought to report the 5-year outcomes of everolimus-eluting stents (EES) and paclitaxel-eluting (PES) in an all-comers population undergoing percutaneous coronary intervention (PCI). The medium-term 1 2-year results prospective randomized COMPARE trial (A Trial Everolimus-Eluting Stents Paclitaxel-Eluting for Coronary Revascularization Daily Practice) showed superior clinical with EES compared PES PCI population. Whether this benefit is sustained over longer-term follow-up unknown....
Proangiogenic hematopoietic and endothelial progenitor cells (EPCs) contribute to postnatal neovascularization, but the mechanisms regulating differentiation lineage are unclear.To elucidate epigenetic control of gene expression in proangiogenic EPCs.Here we demonstrate that nitric oxide synthase (eNOS) promoter is epigenetically silenced (early EPCs), CD34(+) cells, mesoangioblasts by DNA methylation prominent repressive histone H3K27me3 marks. In order reverse silencing facilitate...
The effect of administering a crushed prasugrel loading dose is uncertain in patients presenting with large myocardial infarction and ST-segment elevation (STEMI).
Early treatment with a potent oral platelet P2Y12 inhibitor is recommended in patients presenting ST-segment-elevation myocardial infarction scheduled to undergo primary percutaneous coronary intervention (pPCI). The impact on reperfusion of crushed tablets, which lead more prompt and inhibition, unknown. We conducted randomized controlled, multicenter trial the Netherlands, enrolling pPCI. Patients were randomly allocated receive ambulance, before transfer, 60-mg loading dose prasugrel...
Background— To assess the vessel-healing pattern of Ultimaster drug-eluting stent using optical frequency domain imaging. Our hypothesis is that biodegradable polymer-based technology allows complete very early strut coverage. Methods and Results— The DISCOVERY 1TO3 study (Evaluation With OFDI Strut Coverage Terumo New Drug Eluting Stent Biodegradable Polymer at 1, 2, 3 Months) a prospective, single-arm, multicenter study. A total 60 patients with multivessel disease requiring staged...
The aim of this analysis was to compare the long-term safety and efficacy biodegradable polymer biolimus-eluting stent (BES) with that durable everolimus-eluting (EES).The COMPARE II study a prospective, randomised, multicentre, all-comers trial in which 2,707 patients were randomly allocated (2:1) BES or EES. pre-specified endpoint at three years major adverse cardiac events (MACE), composite death, non-fatal myocardial infarction (MI), target vessel revascularisation (TVR). Moreover,...
Objectives To validate the Global Registry of Acute Coronary Events (GRACE) risk score and examine extent impact risk–treatment paradox in contemporary patients with acute coronary syndrome (ACS). Methods Data from 5015 ACS enrolled FORCE-ACS registry between January 2015 December 2019 were used for model validation. The performance GRACE predicting in-hospital 1-year mortality was evaluated based on indices discrimination calibration. Differences delivery guideline-recommended care among...
Background:This study evaluated the safety and efficacy of RESOLUTETMzotarolimus-eluting stent (R-ZES; Medtronic, Inc, Santa Rosa, CA, USA) in Japanese patients for treatment de novo native coronary lesions.Methods Results:Both RESOLUTE Japan (R-Japan) Small Vessel Study (R-Japan SVS) were prospective, multicenter, single-arm observational studies. R-Japan enrolled 100 (reference vessel diameter, 2.5–3.5 mm) SVS 65 (at least 1 lesion suitable 2.25-mm stent) treated with R-ZES. In R-Japan,...
We sought to assess if bivalirudin use during balloon aortic valvuloplasty (BAV) would affect clinical outcomes compared with heparin.We the of consecutive patients who underwent elective or urgent BAV intraprocedural heparin at two high-volume centres. All in-hospital events post were adjudicated by an independent, blinded committee. Of 427 patients, 223 (52.2%) received and 204 (47.8%) heparin. Compared heparin, had significantly less major bleeding (4.9% vs. 13.2%, p=0.003). Net adverse...
The aim of this study was to investigate the impact dual antiplatelet therapy (DAPT) termination on late and very scaffold thrombosis (ScT) in patients treated with Absorb bioresorbable vascular (BVS).Data from registries three centres were pooled (808 patients). To effect DAPT ScT after a minimum six months, we selected subgroup ("DAPT cohort" 685 patients) known status >6 months excluded use oral anticoagulants early ScT. In cohort, definite/probable incidence for period compared...
Diagnostic and treatment strategies for acute coronary syndrome have improved dramatically over the past few decades, but mortality recurrent myocardial infarction rates remain high. An aging population with increasing co-morbidities heralds new clinical challenges. Therefore, in order to evaluate improve current strategies, detailed information on presentation, follow-up real-world patients is needed. The Future Optimal Research Care Evaluation Acute Coronary Syndrome (FORCE-ACS) registry...
Bioresorbable vascular scaffolds (BVS) represent a novel therapeutic option for the treatment of coronary artery diseases. The objective this study was to evaluate feasibility BVS implantation in complex chronic total occlusions (CTO).The present report is multicentre registry evaluating results after deployment challenging CTO lesions, defined as J-CTO score ≥2 (difficult or very difficult). A 105 patients were included analysis. mean 2.61 52.4%, difficult 47.6%). Device success and...
A genotype-guided P2Y12-inhibitor de-escalation strategy, switching acute coronary syndrome (ACS) patients without a CYP2C19 loss-of-function allele from ticagrelor or prasugrel to clopidogrel, has shown reduce bleeding risk affecting effectivity of therapy by increasing ischemic risk. We estimated the cost-effectiveness this personalized approach compared standard dual antiplatelet (DAPT; aspirin plus ticagrelor/prasugrel) in Netherlands.